2 February

World Health Assembly Executive Board 136: YP-CDN and HAI intervention on the progress achieved in the prevention and control of non-communicable diseases

5 June

Hoping for "harmony" on global antibiotic resistance strategy

28 May

Week in review: Outcomes from WHA67

28 May

Progress on access to medicines at WHA67, but WHO funding sorely needed

26 May

World Health Assembly: HAI and ARC intervention on antimicrobial resistance, including antibiotic resistance

26 May

World Health Assembly 67: HAI and KEI intervention on the Consultative Expert Working Group on Research and Development

26 May

World Health Assembly 67: HAI intervention on access to essential medicines

20 May

World Health Assembly 67: HAI intervention on the WHO's framework of engagement with non-state actors

10 April

Tamiflu review shows desperate need for full clinical trials data transparency

3 March

New materials help assess medicines policies and interventions

24 February

A new (and improved) model to regulate pharmaceutical promotion

12 February

Enhancing accountability in the medicines market: The Medicines Transparency Alliance

31 January

Leaks and Lies: Pharma’s strategy to derail South Africa’s intellectual property reforms exposed

30 January

Selected R&D demonstration projects disappointing: Innovation models with new incentive mechanisms needed

15 May

Bracing for another delay – open innovation at the WHO?

20 May

Statement on conflicts of interest delivered at WHA on behalf of HAI, Berne Declaration, KEI, TWN, PHM, IBFAN

17 May

Conflicts of Interest and the Future of Financing for WHO.

29 April

Foundations: Conlicts of interests and Democracy issues

14 June

Innovation & Access at the EU High Level Event on Global Health

29 March

No NGO briefings will be allowed during World Health Assembly this year.